Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 54

1.

Hyperprogressive Disease in Patients With Advanced Non-Small Cell Lung Cancer Treated With PD-1/PD-L1 Inhibitors or With Single-Agent Chemotherapy.

Ferrara R, Mezquita L, Texier M, Lahmar J, Audigier-Valette C, Tessonnier L, Mazieres J, Zalcman G, Brosseau S, Le Moulec S, Leroy L, Duchemann B, Lefebvre C, Veillon R, Westeel V, Koscielny S, Champiat S, Ferté C, Planchard D, Remon J, Boucher ME, Gazzah A, Adam J, Bria E, Tortora G, Soria JC, Besse B, Caramella C.

JAMA Oncol. 2018 Sep 6. doi: 10.1001/jamaoncol.2018.3676. [Epub ahead of print]

PMID:
30193240
2.

Sunitinib Prior to Planned Nephrectomy in Metastatic Renal Cell Carcinoma: Angiogenesis Biomarkers Predict Clinical Outcome in the Prospective Phase II PREINSUT Trial.

Mauge L, Mejean A, Fournier L, Pereira H, Etienne-Grimaldi MC, Levionnois E, Caty A, Abadie-Lacourtoisie S, Culine S, Le Moulec S, Linassier C, Théodore C, Ravaud A, Albiges L, Grine A, Tartour E, Milano G, Gille AS, Verkarre V, Helley D, Oudard S; PREINSUT study group.

Clin Cancer Res. 2018 Jul 30. doi: 10.1158/1078-0432.CCR-18-1045. [Epub ahead of print]

PMID:
30061359
3.

Targeting ERBB2 mutations in solid tumors: biological and clinical implications.

Cousin S, Khalifa E, Crombe A, Laizet Y, Lucchesi C, Toulmonde M, Le Moulec S, Auzanneau C, Soubeyran I, Italiano A.

J Hematol Oncol. 2018 Jun 25;11(1):86. doi: 10.1186/s13045-018-0630-4.

4.

Efficacy of cabazitaxel rechallenge in heavily treated patients with metastatic castration-resistant prostate cancer.

Thibault C, Eymard JC, Birtle A, Krainer M, Baciarello G, Fléchon A, Le Moulec S, Spaeth D, Laguerre B, Caffo O, Deville JL, Beuzeboc P, Hasbini A, Gross-Goupil M, Helissey C, Bennamoun M, Hardy-Bessard AC, Oudard S.

Eur J Cancer. 2018 Jul;97:41-48. doi: 10.1016/j.ejca.2018.03.008. Epub 2018 Apr 7.

PMID:
29636272
5.

Results of the FLAC European Database of Metastatic Castration-Resistant Prostate Cancer Patients Treated With Docetaxel, Cabazitaxel, and Androgen Receptor-Targeted Agents.

Angelergues A, Efstathiou E, Gyftaki R, Wysocki PJ, Lainez N, Gonzalez I, Castellano DE, Ozguroglu M, Carbonero IG, Flechon A, Borrega P, Guillot A, Balea BC, Le Moulec S, Esteban E, Munarriz J, Rubio G, Birtle AJ, Delanoy N, Bellmunt J, Oudard S.

Clin Genitourin Cancer. 2018 Aug;16(4):e777-e784. doi: 10.1016/j.clgc.2018.02.016. Epub 2018 Feb 23.

PMID:
29550200
6.

A fatal allo- and immune-mediated thrombocytopenia with a PD-L1 inhibitor.

Leroy L, Lafarge X, Blouin L, Bijou F, Durrieu F, Olivier E, Le Moulec S.

Ann Oncol. 2018 Feb 1;29(2):514-515. doi: 10.1093/annonc/mdx693. No abstract available.

PMID:
29088313
7.

[Principles, modalities and indications of the administration of Radium in cancers, focus on metastatic prostate cancer: State of arts].

Bertolaso P, Leroy L, Gross-Goupil M, Aupee O, Ravaud A, Roubaud G, Cazeau AL, Le Moulec S.

Bull Cancer. 2017 Sep;104(9):762-770. doi: 10.1016/j.bulcan.2017.06.011. Epub 2017 Aug 7. Review. French.

PMID:
28797482
8.

[Cabozantinib: Mechanism of action, efficacy and indications].

Cochin V, Gross-Goupil M, Ravaud A, Godbert Y, Le Moulec S.

Bull Cancer. 2017 May;104(5):393-401. doi: 10.1016/j.bulcan.2017.03.013. Epub 2017 May 3. French.

PMID:
28477875
9.

[Management of a progressing prostate cancer: results of a national study].

Rozet F, Roupret M, Hennequin C, Massard C, Blanchard P, Le Moulec S.

Prog Urol. 2017 May;27(6):381-388. doi: 10.1016/j.purol.2017.02.001. Epub 2017 Apr 6. French.

PMID:
28392429
10.

Clinical impact of extensive molecular profiling in advanced cancer patients.

Cousin S, Grellety T, Toulmonde M, Auzanneau C, Khalifa E, Laizet Y, Tran K, Le Moulec S, Floquet A, Garbay D, Robert J, Hostein I, Soubeyran I, Italiano A.

J Hematol Oncol. 2017 Feb 8;10(1):45. doi: 10.1186/s13045-017-0411-5.

11.

Phase III Study of Cabozantinib in Previously Treated Metastatic Castration-Resistant Prostate Cancer: COMET-1.

Smith M, De Bono J, Sternberg C, Le Moulec S, Oudard S, De Giorgi U, Krainer M, Bergman A, Hoelzer W, De Wit R, Bögemann M, Saad F, Cruciani G, Thiery-Vuillemin A, Feyerabend S, Miller K, Houédé N, Hussain S, Lam E, Polikoff J, Stenzl A, Mainwaring P, Ramies D, Hessel C, Weitzman A, Fizazi K.

J Clin Oncol. 2016 Sep 1;34(25):3005-13. doi: 10.1200/JCO.2015.65.5597. Epub 2016 Jul 11.

PMID:
27400947
12.

Phenotypic and genetic heterogeneity of tumor tissue and circulating tumor cells in patients with metastatic castration-resistant prostate cancer: A report from the PETRUS prospective study.

Massard C, Oulhen M, Le Moulec S, Auger N, Foulon S, Abou-Lovergne A, Billiot F, Valent A, Marty V, Loriot Y, Fizazi K, Vielh P, Farace F.

Oncotarget. 2016 Aug 23;7(34):55069-55082. doi: 10.18632/oncotarget.10396.

13.

[Prognosis prediction of febrile neutropenia by MASCC score: A retrospective study].

Cervetti L, Vallard A, Le Moulec S, Espenel S, Falk AT, Ben Mrad M, Guy JB, Diao P, Méry B, Langrand-Escure J, Ferrand FR, Rivoirard R, Ceccaldi B, Védrine L, Magné N, Chargari C.

Bull Cancer. 2016 Jun;103(6):561-70. doi: 10.1016/j.bulcan.2016.03.008. Epub 2016 May 12. French.

PMID:
27181759
14.

Vimentin and Ki67 expression in circulating tumour cells derived from castrate-resistant prostate cancer.

Lindsay CR, Le Moulec S, Billiot F, Loriot Y, Ngo-Camus M, Vielh P, Fizazi K, Massard C, Farace F.

BMC Cancer. 2016 Feb 29;16:168. doi: 10.1186/s12885-016-2192-6.

15.

Differential Effect on Bone Lesions of Targeting Integrins: Randomized Phase II Trial of Abituzumab in Patients with Metastatic Castration-Resistant Prostate Cancer.

Hussain M, Le Moulec S, Gimmi C, Bruns R, Straub J, Miller K; PERSEUS Study Group.

Clin Cancer Res. 2016 Jul 1;22(13):3192-200. doi: 10.1158/1078-0432.CCR-15-2512. Epub 2016 Feb 2.

16.

Quick, non-invasive and quantitative assessment of small fiber neuropathy in patients receiving chemotherapy.

Saad M, Psimaras D, Tafani C, Sallansonnet-Froment M, Calvet JH, Vilier A, Tigaud JM, Bompaire F, Lebouteux M, de Greslan T, Ceccaldi B, Poirier JM, Ferrand FR, Le Moulec S, Huillard O, Goldwasser F, Taillia H, Maisonobe T, Ricard D.

J Neurooncol. 2016 Apr;127(2):373-80. doi: 10.1007/s11060-015-2049-x. Epub 2016 Jan 9.

PMID:
26749101
17.

Bevacizumab in Patients with Nonsquamous Non-Small Cell Lung Cancer and Asymptomatic, Untreated Brain Metastases (BRAIN): A Nonrandomized, Phase II Study.

Besse B, Le Moulec S, Mazières J, Senellart H, Barlesi F, Chouaid C, Dansin E, Bérard H, Falchero L, Gervais R, Robinet G, Ruppert AM, Schott R, Léna H, Clément-Duchêne C, Quantin X, Souquet PJ, Trédaniel J, Moro-Sibilot D, Pérol M, Madroszyk AC, Soria JC.

Clin Cancer Res. 2015 Apr 15;21(8):1896-903. doi: 10.1158/1078-0432.CCR-14-2082. Epub 2015 Jan 22.

18.

Safety of spinal radiotherapy in metastatic cancer patients receiving bevacizumab therapy: a bi-institutional case series.

Mbagui R, Langrand-Escure J, Annede P, Mery B, Ceccaldi B, Guy JB, Falk AT, Bauduceau O, Bosacki C, Jacob J, Helissey C, Ferrand FR, Dulou R, Le Moulec S, Vedrine L, Magné N, Chargari C.

Anticancer Drugs. 2015 Apr;26(4):443-7. doi: 10.1097/CAD.0000000000000204.

PMID:
25569704
19.

Parotid gland metastasis from prostate cancer: is docetaxel still the best treatment option?

Hélissey C, Rouanne M, Arnaud FX, Le Moulec S.

Anticancer Drugs. 2015 Mar;26(3):367-70. doi: 10.1097/CAD.0000000000000188.

PMID:
25486600
20.

Leiomyosarcoma of the superior vena cava.

de Chaumont A, Pierret C, de Kerangal X, Le Moulec S, Laborde F.

Ann Thorac Surg. 2014 Aug;98(2):725-7. doi: 10.1016/j.athoracsur.2013.09.106.

PMID:
25087805
21.

Cabazitaxel Remains Active in Patients Progressing After Docetaxel Followed by Novel Androgen Receptor Pathway Targeted Therapies.

Al Nakouzi N, Le Moulec S, Albigès L, Wang C, Beuzeboc P, Gross-Goupil M, de La Motte Rouge T, Guillot A, Gajda D, Massard C, Gleave M, Fizazi K, Loriot Y.

Eur Urol. 2015 Aug;68(2):228-35. doi: 10.1016/j.eururo.2014.04.015. Epub 2014 May 2.

PMID:
24837187
22.

Prostate-specific antigen flare induced by cabazitaxel-based chemotherapy in patients with metastatic castration-resistant prostate cancer.

Angelergues A, Maillet D, Fléchon A, Ozgüroglu M, Mercier F, Guillot A, Le Moulec S, Gravis G, Beuzeboc P, Massard C, Fizazi K, de La Motte Rouge T, Delanoy N, Elaidi RT, Oudard S.

Eur J Cancer. 2014 Jun;50(9):1602-9. doi: 10.1016/j.ejca.2014.03.015. Epub 2014 Apr 8.

PMID:
24725337
23.

Combination of paclitaxel and bevacizumab in heavily pre-treated non-small-cell lung cancer (NSCLC) patients: a case series study on 15 patients.

Le Moulec S, Hadoux J, Gontier E, Chargari C, Helissey C, Lamand V, Tanz R, Farace F, Vedrine L, Bonardel G, Soria JC, Besse B.

Bull Cancer. 2013 Dec;100(12):30-7. doi: 10.1684/bdc.2013.1864.

PMID:
24316967
24.

[Neuroendocrine carcinoma of the digestive tract: a literature review].

Jacob J, Chargari C, Helissey C, Ferrand FR, Ceccaldi B, Le Moulec S, Bauduceau O, Fayolle M, Védrine L.

Rev Med Interne. 2013 Nov;34(11):700-5. doi: 10.1016/j.revmed.2013.02.013. Epub 2013 Jul 18. Review. French.

PMID:
23871177
25.

First assessment of whole-brain radiation therapy combined with pemetrexed-based chemotherapy in non-small-cell lung carcinoma: data on safety and efficacy.

Chargari C, Pacaut C, Le Moulec S, Moriceau G, Moussaid Y, Rivoirard R, Dulou R, Jacob J, Guy JB, Bauduceau O, Ceccaldi B, Védrine L, Fournel P, Magné N.

Anticancer Drugs. 2013 Aug;24(7):736-42. doi: 10.1097/CAD.0b013e328360974d.

PMID:
23542752
26.

Ipilimumab in cancer patients: the issue of early metabolic response.

Chargari C, Le Moulec S, Bonardel G, Foehrenbach H, Védrine L.

Anticancer Drugs. 2013 Mar;24(3):324-6. doi: 10.1097/CAD.0b013e32835dbaaf. No abstract available.

PMID:
23348246
27.

[Fever and cancer: components of diagnosis for optimal management].

Moussaid Y, Bertaux M, Chargari C, Helissey C, Le Moulec S, Errihani H, Vedrine L.

Rev Med Interne. 2013 Sep;34(9):545-52. doi: 10.1016/j.revmed.2012.10.368. Epub 2012 Nov 27. Review. French.

PMID:
23199412
28.

Knowledge and screening of testicular cancer in the French Armed Forces: a prospective study.

Kedzierewicz R, Chargari C, Le Moulec S, Ferrandez NJ, Ceccaldi B, Houlgatte A, Vedrine L.

Mil Med. 2011 Oct;176(10):1188-92.

PMID:
22128657
29.

Gemcitabine or gemcitabine plus oxaliplatin in the first-line treatment of patients with advanced transitional cell carcinoma of the urothelium unfit for cisplatin-based chemotherapy: a randomized phase 2 study of the French Genitourinary Tumor Group (GETUG V01).

Culine S, Fléchon A, Guillot A, Le Moulec S, Pouessel D, Rolland F, Ravaud A, Houédé N, Mignot L, Joly F, Oudard S, Gourgou S.

Eur Urol. 2011 Dec;60(6):1251-7. doi: 10.1016/j.eururo.2011.08.072. Epub 2011 Sep 10.

PMID:
21924547
30.

A direct comparison of CellSearch and ISET for circulating tumour-cell detection in patients with metastatic carcinomas.

Farace F, Massard C, Vimond N, Drusch F, Jacques N, Billiot F, Laplanche A, Chauchereau A, Lacroix L, Planchard D, Le Moulec S, André F, Fizazi K, Soria JC, Vielh P.

Br J Cancer. 2011 Sep 6;105(6):847-53. doi: 10.1038/bjc.2011.294. Epub 2011 Aug 9.

31.

[Cell cycle and molecular targets: CDK inhibition].

Carassou P, Meijer L, Le Moulec S, Aoun J, Bengrine-Lefèvre L.

Bull Cancer. 2012 Feb 1;99(2):163-71. doi: 10.1684/bdc.2011.1383. Review. French.

32.

First case of posterior reversible encephalopathy syndrome associated with vinflunine.

Helissey C, Chargari C, Lahutte M, Ricard D, Vedrine L, Ceccaldi B, Le Moulec S.

Invest New Drugs. 2012 Oct;30(5):2032-4. doi: 10.1007/s10637-011-9712-7. Epub 2011 Jul 5. No abstract available.

PMID:
21728021
33.

[Molecules involved in apoptosis regulation as therapeutic targets in oncology].

Lheureux S, Le Moulec S.

Bull Cancer. 2011 Oct;98(9):1029-36. doi: 10.1684/bdc.2011.1381. Review. French.

34.

Stemness markers characterize IGR-CaP1, a new cell line derived from primary epithelial prostate cancer.

Chauchereau A, Al Nakouzi N, Gaudin C, Le Moulec S, Compagno D, Auger N, Bénard J, Opolon P, Rozet F, Validire P, Fromont G, Fizazi K.

Exp Cell Res. 2011 Feb 1;317(3):262-75. doi: 10.1016/j.yexcr.2010.10.012. Epub 2010 Oct 23.

PMID:
20974126
35.

Whole-brain radiation therapy in breast cancer patients with brain metastases.

Chargari C, Campana F, Pierga JY, Védrine L, Ricard D, Le Moulec S, Fourquet A, Kirova YM.

Nat Rev Clin Oncol. 2010 Nov;7(11):632-40. doi: 10.1038/nrclinonc.2010.119. Epub 2010 Jul 13. Review.

PMID:
20625374
36.

Pancreatic metastasis from prostate cancer.

Jacob J, Chargari C, Bauduceau O, Fayolle M, Ceccaldi B, Prat F, Le Moulec S, Vedrine L.

Case Rep Med. 2010;2010:826273. doi: 10.1155/2010/826273. Epub 2010 May 23.

37.

[Targeting KRAS pathway in NSCLC therapy].

Le Moulec S, Loriot Y, Soria JC.

Bull Cancer. 2009 Dec;96 Suppl:S69-74. doi: 10.1684/bdc.2009.0998. French.

PMID:
20034872
38.

Blood diffusion and Th1-suppressive effects of galectin-9-containing exosomes released by Epstein-Barr virus-infected nasopharyngeal carcinoma cells.

Klibi J, Niki T, Riedel A, Pioche-Durieu C, Souquere S, Rubinstein E, Le Moulec S, Guigay J, Hirashima M, Guemira F, Adhikary D, Mautner J, Busson P.

Blood. 2009 Feb 26;113(9):1957-66. doi: 10.1182/blood-2008-02-142596. Epub 2008 Nov 12. Erratum in: Blood. 2009 Oct 29;114(18):3974. Moulec, Sylvestre L E [corrected to Le Moulec, Sylvestre].

39.

Reapprasial of the role of endocrine therapy in meningioma management.

Chargari C, Védrine L, Bauduceau O, Le Moulec S, Ceccaldi B, Magné N.

Endocr Relat Cancer. 2008 Dec;15(4):931-41. doi: 10.1677/ERC-08-0083. Epub 2008 Jul 16. Review.

PMID:
18632875
40.

[Managing nausea and vomiting in thoracic oncology].

Le Moulec S, Vedrine L.

Rev Pneumol Clin. 2008 Apr;64(2):76-80. doi: 10.1016/j.pneumo.2008.04.001. Epub 2008 Jun 6. Review. French.

PMID:
18589287
41.

[Prostate cancer and disseminated intravascular coagulation: review of the literature].

Chargari C, Vedrine L, Bauduceau O, Le Moulec S, Fayolle M, Ceccaldi B, Houlgatte A.

Prog Urol. 2008 Jan;18(1):9-13. doi: 10.1016/j.purol.2007.12.001. Epub 2008 Mar 4. Review. French.

PMID:
18342149
42.

[Cancer chemotherapy of the upper aerodigestive tract].

Védrine L, Chargari C, Le Moulec S, Fayolle M, Ceccaldi B, Bauduceau O.

Cancer Radiother. 2008 Mar;12(2):110-9. doi: 10.1016/j.canrad.2007.11.005. Epub 2008 Jan 9. Review. French.

PMID:
18187355
43.

[Favorable outcome of gemcitabine-induced acute respiratory distress syndrome].

Bonnichon A, Vedrine L, Aletti M, Le Moulec S, Borne M, Margery J, Bauduceau O, Fayolle M, Ceccaldi B.

Rev Pneumol Clin. 2007 Dec;63(6):379-83. French.

PMID:
18166944
44.

[Craniopharyngioma].

Chargari C, Bauduceau O, Le Moulec S, Vedrine L, Ceccaldi B.

Rev Prat. 2007 Oct 31;57(16):1756. French. No abstract available.

PMID:
18092716
45.

[Craniopharyngiomas: role of radiotherapy].

Chargari C, Bauduceau O, Bauduceau B, Camparo P, Ceccaldi B, Fayolle M, Le Moulec S, Védrine L.

Bull Cancer. 2007 Nov;94(11):987-94. Review. French.

46.

[Non-seminomatous germ cell tumour].

Chargari C, Védrine L, Le Moulec S, Bonardel G.

Rev Prat. 2007 Apr 15;57(7):707. French. No abstract available.

PMID:
17626314
47.

[Testicular metastasis of prostatic adenocarcinoma: a case report].

Bauduceau O, Vedrine L, Chargari C, Ceccaldi B, Le Moulec S, Houlgatte A.

Prog Urol. 2007 Apr;17(2):251-2. French.

PMID:
17489329
48.

[Combined chemotherapy and radiation therapy for intracranial germinomas. The Val-de-Grace hospital experience].

Védrine L, Bauduceau O, Fayolle M, Le Moulec S, Ceccaldi B.

Cancer Radiother. 2005 Sep;9(5):335-40. Epub 2005 Jul 12. French.

PMID:
16019248
49.

[Spinal cord compression from a malignant pleural mesothelioma].

Margery J, Grassin F, Le Moulec S, Ruffié P.

Rev Pneumol Clin. 2005 Apr;61(2):112-4. French.

PMID:
16012365
50.

[Metastatic obstruction of the small bowel complicating malignant pleural mesothelioma].

Margery J, Grassin F, Bredin C, Le Moulec S, Warlaumont C, Ruffie P.

Gastroenterol Clin Biol. 2004 Jun-Jul;28(6-7 Pt 1):616-7. French. No abstract available.

Supplemental Content

Loading ...
Support Center